Immunodermatology

At Johnson & Johnson, we are steadfast in our commitment to address unmet need, uncover novel treatment approaches, and work collaboratively to deliver transformational therapies for patients living with chronic immune-mediated diseases. We understand that significant unmet need remains in many of these diseases, and that patients around the world are struggling to find safe, effective treatments, and maintain symptom-free remission.

Building upon our portfolio of transformational advanced therapies, which will continue to offer important treatment options for patients with immune-mediated diseases, we believe the pursuit of novel oral therapies is critical to reaching the many people still not receiving advanced therapies and ensuring patients have more options that offer the potential for remission.

Driven by a relentless commitment to patients, we continue to pioneer research to achieve our vision of restoring health for all patients with immune-mediated diseases.